ASH 2018 | 7-year follow-up of ibrutinib monotherapy for R/R and first-line CLL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
The safety and efficacy of single-agent ibrutinib was investigated in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the first-line and relapsed/refractory settings. In this interview, Susan O’Brien, MD, of the University of California, Irvine, CA, discusses the data from the longest follow-up available, up to 7-years, from the Phase Ib/II PCYC-1102 trial (NCT01105247), and PCYC-1103 extension study (NCT01109069). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. O’Brien reveals the sustained activity of single-agent ibrutinib, including in those with high-risk genomic factors, with the addition of no new safety signals or late toxicities.
Get great new content delivered to your inboxSign up